{"created":"2023-05-15T14:37:49.057540+00:00","id":48793,"links":{},"metadata":{"_buckets":{"deposit":"57b340a2-faf3-4f28-9eda-3c509002a5c1"},"_deposit":{"created_by":1,"id":"48793","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"48793"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00048793","sets":["1"]},"author_link":["491373","491376","491372","491379","491375","491380","491378","491371","491377","491374"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-02","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"16","bibliographicPageEnd":"12940","bibliographicPageStart":"12932","bibliographicVolumeNumber":"9","bibliographic_titles":[{"bibliographic_title":"Oncotarget"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Purpose: To evaluate the efficacy and safety of carbon-ion radiotherapy (CIRT) for patients with lacrimal gland carcionmas (LGCs) with extraorbital extension \nResults:  The median follow-up period was 53.7  months. The 5-year local control and overall survival rates were 62% and 65%, respectively. Regarding late toxicities, 12 patients (36.4%) developed Grade 4 optic nerve disorders, including visual losses of the disweased side (N = 8;66.7%), and 1 patient (3.0%) developed a Grade 3 optic nerve disorder. Three patients (9.0%) developed Grade 3 cataracts, 3 (9.0%) developed glaucoma, and 1 (3.0%) developed retinopathy. Two patients (6.1%) had Grade 4 central nervous system necrosis. No Grade 5 late toxicities were observed. The 5-year preservation rate of the ipsilateral eyeball was 86%.\nConclusion:  Definitive CIRT is effective for LGCs with extraorbital extension with acceptable toxicity.\nMethods:  Thirty-three patients treated with CIRT at our institution were analyzed. Sixteen patients (48.5%) had adenoid cystic carcinoma, 8 (24.2%) had  adnocarcinoma not otherwise specified, and 9 (27.3%) had other types of the disease.  Thirty patients (90.9%) had T4c tumors. the prescribed doses were 57.6 Gy (relative biological effectiveness [RBE]) (N = 18; 54.5%) and 64.0 gy(RBE) (N = 15;45.5%) in 16 fractions.","subitem_description_type":"Abstract"}]},"item_8_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Inpact Journals"}]},"item_8_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.18632/oncotarget.24390 ","subitem_relation_type_select":"DOI"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":" 1949-2553","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Hayashi, Kazuhiko"}],"nameIdentifiers":[{"nameIdentifier":"491371","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Koto, Masashi"}],"nameIdentifiers":[{"nameIdentifier":"491372","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ikawa, Hiroaki"}],"nameIdentifiers":[{"nameIdentifier":"491373","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ogawa, Kazuhiko"}],"nameIdentifiers":[{"nameIdentifier":"491374","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kamada, Tadashi"}],"nameIdentifiers":[{"nameIdentifier":"491375","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"林 和彦","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"491376","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"小藤 昌志","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"491377","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"伊川 裕明","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"491378","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"小川 和彦","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"491379","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鎌田 正","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"491380","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":" Efficacy and safety of carbon-ion radiotherapy for lacrimal gland carcinomas with extraorbital extension: a retrospective cohort study","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":" Efficacy and safety of carbon-ion radiotherapy for lacrimal gland carcinomas with extraorbital extension: a retrospective cohort study"}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-04-23"},"publish_date":"2018-04-23","publish_status":"0","recid":"48793","relation_version_is_last":true,"title":[" Efficacy and safety of carbon-ion radiotherapy for lacrimal gland carcinomas with extraorbital extension: a retrospective cohort study"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T23:24:15.682749+00:00"}